Detalus Advisors LLC Acquires 256 Shares of Eli Lilly and Company (NYSE:LLY)

Detalus Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 48.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 785 shares of the company’s stock after purchasing an additional 256 shares during the period. Detalus Advisors LLC’s holdings in Eli Lilly and Company were worth $711,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares in the last quarter. Capital World Investors raised its stake in Eli Lilly and Company by 0.3% in the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after buying an additional 89,720 shares in the last quarter. Norges Bank bought a new position in Eli Lilly and Company in the fourth quarter worth about $5,992,890,000. Capital Research Global Investors raised its stake in Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares in the last quarter. Finally, Capital International Investors raised its stake in Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after buying an additional 335,560 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on LLY. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, August 19th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Truist Financial restated a “buy” rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Finally, Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 22,206 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $822.11, for a total value of $18,255,774.66. Following the sale, the insider now owns 98,401,604 shares in the company, valued at $80,896,942,664.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Lilly Endowment Inc sold 22,206 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $822.11, for a total value of $18,255,774.66. Following the sale, the insider now owns 98,401,604 shares in the company, valued at $80,896,942,664.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,120,089 shares of company stock worth $990,278,343. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE:LLY traded down $5.54 during trading on Wednesday, reaching $948.94. 1,679,095 shares of the stock traded hands, compared to its average volume of 3,081,237. The stock has a 50-day moving average of $888.89 and a two-hundred day moving average of $818.23. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market cap of $901.88 billion, a P/E ratio of 139.76, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.